1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics 2020 - United Kingdom

Healthcare Analysis & Statistics 2020 - United Kingdom

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

All regions

1-12 of 12 reports

Rheumatoid Arthritis: KOL Insight [2018]

  • $ 9000
  • March 2018
  • 1 pages

How is Olumiant impacting the RA treatment landscape? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s ...

  • Health Services
  • Healthcare
  • Medical Biotechnology
  • United Kingdom
  • United States

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • $ 6948
  • March 2018
  • 1 pages

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team ...

  • Health Services
  • Healthcare
  • United Kingdom

Market Access Impact: Melanoma (EU5) 2018

  • $ 5865
  • February 2018
  • 1 pages

Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out? In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two ...

  • Health Care Provider
  • Health Services
  • Healthcare
  • United Kingdom
  • United States

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • February 2018
  • 1 pages

Can new biologics breathe fresh competition into the targeted asthma treatment landscape? The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Asthma
  • Healthcare
  • Medical Biotechnology
  • Therapy
  • United Kingdom

Colorectal Cancer [2017]

  • $ 8658
  • September 2017
  • 1 pages

Will new targeted therapies transform the treatment of colorectal cancer? Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal ...

  • Cancer
  • Colorectal Cancer
  • Healthcare
  • Therapy
  • United Kingdom

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2017

  • $ 5637
  • August 2017
  • 1 pages

Eliminating prescription barriers could break the tie at the top of the market The two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share, but one of them benefits ...

  • Health Services
  • Healthcare
  • United Kingdom

Market Access Impact: Multiple Sclerosis (EU5) 2017

  • $ 5637
  • July 2017
  • 1 pages

Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5 In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market ...

  • Health Services
  • Healthcare
  • France
  • United Kingdom
  • Market Shares

Medical Affairs Reputations: Melanoma (EU5) 2017

  • $ 6755
  • July 2017
  • 1 pages

Find out what the leading team gets right, and what the trailing team gets wrong The medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists ...

  • Health Services
  • Healthcare
  • United Kingdom

Market Access Impact (EU5) [Melanoma]

  • $ 5637
  • February 2017
  • 1 pages

Description Two brands are neck and neck for 2nd place. Would eliminating barriers break the tie? In the EU5, market barriers affect nearly a quarter of all melanoma prescriptions, giving the top brand ...

  • Health Services
  • Healthcare
  • United Kingdom
  • United States

Prostate Cancer: KOL Insight 2016

  • $ 8658
  • November 2016
  • 1 pages

Description PARP inhibitors and second-generation hormonal therapies driving KOL excitement Good news for late-stage prostate cancer patients: a host of new therapies are in the pipeline, indications ...

  • Health Services
  • Healthcare
  • Therapy
  • United Kingdom
  • United States

Medical Affairs Reputations: Rheumatoid Arthritis (EU) 2016

  • $ 6755
  • October 2016
  • 1 pages

Does your medical affairs team need a wakeup call? Our survey results say yes. In the rheumatoid arthritis (RA) market, not even the leading medical affairs teams are doing a great job of delivering the ...

  • Health Services
  • Healthcare
  • Medical Biotechnology
  • United Kingdom

Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?

  • $ 781
  • April 2014
  • 1 pages

According to analysts at Barclays, oncology continues to attract around one-third of pharma's total R&D investment. This trend is driven by a number of factors, not least the commercial opportunity ...

  • Healthcare
  • Therapy
  • United Kingdom


About 12000 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Pathology Statistics in the UK

  • July 2020
  • 28 pages
  • Healthcare
  • Pathology
  • United Kingdom
  • Demographic

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on